{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-24-000049","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.433040+00:00","generated_at":"2026-06-02T10:36:37.957310+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BeiGene Q1 2024 revenue up 82% to $752M; BRUKINSA sales $489M","bullets":["Total Q1 product revenue $747M (+82% YoY); total revenue $752M; BRUKINSA revenue $489M.","BRUKINSA U.S. sales grew 153% and Europe 243% YoY; fifth FDA approval gives broadest BTKi label.","GAAP operating loss narrowed to $261M from $371M; adjusted operating loss $147M vs $276M.","TEVIMBRA now approved in U.S. and Europe; advancing late-stage pipeline including sonrotoclax and BTK CDAC.","Company says progressing toward sustainable profitability with improved operating leverage."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-24-000049","json":"https://secwatch.observer/filing/0001651308-24-000049.json","markdown":"https://secwatch.observer/filing/0001651308-24-000049.md","text":"https://secwatch.observer/filing/0001651308-24-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000049/0001651308-24-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000049/bgne-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T10:36:37.957310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9756978984f49794f848fe59dcc51d17f6575eea","claim":"BeOne Medicines Ltd. reported the three months ended March 31, 2024 results: revenue $752 million.","evidence_excerpt":"as Exhibit 99.1 to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- BeiGene Reports First Quarter 2024 Financial Results and Business Updates • Total revenues of $752 million in the first quarter, including product revenue of $747 million, an 82% increase from the prior-year period • BRUKINSA revenue of $489 million, driven by growth in the U.S. and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000049/0001651308-24-000049-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$752 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}